Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07471880) titled 'A Phase II Randomized Controlled Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head' on Feb. 28.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.

Condition: Osteonecrosis Osteonecrosis of the Femoral Head

Intervention: Drug: RAB001 high dose Drug: RAB001 medium dose Drug: RAB001 low dose

Recruitment Status: Not recruiting

Phase: Pha...